Clinical observation of pemetrexed on advanced non-small-cell lung cancer

Zheng, Yang; Ge, Wei; Zhang, Ling; Zhao, Zhenyu; Jie, Fangfang

doi:10.1007/s10330-011-0757-z

Cited by 4 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The flow of study selection is shown in Figure . Of the 3,208 records identified by our literature search, 90 eligible studies with 17,621 patients (9,529, 7,401, and 691 in the gefitinib, erlotinib, and afatinib groups, respectively) were included for this systematic review . Twelve of the 90 studies were available as conference abstracts only .…”

Section: Resultsmentioning

confidence: 99%

Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: A meta‐analysis

Yang

Hackshaw

Feng

et al. 2017

Intl Journal of Cancer

184

121

View full text Add to dashboard Cite

Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non-small cell lung cancer (NSCLC) with proven efficacy. We undertook a systematic review and meta-analysis to synthesize existing studies with direct comparisons of EGFR TKIs in NSCLC in terms of both efficacy and safety. Eight randomized trials and 82 cohort studies with a total of 17,621 patients were included for analysis. Gefitinib and erlotinib demonstrated comparable effects on progression-free survival (hazard ratio [HR], 1.00; 95% confidence interval [CI], 0.95 to 1.04), overall survival (HR, 0.99; 95% CI, 0.93 to 1.06), overall response rate (risk ratio [RR], 1.05; 95% CI, 1.00 to 1.11), and disease control rate (RR, 0.98; 95% CI, 0.96 to 1.01), which did not vary considerably with EGFR mutation status, ethnicity, line of treatment, and baseline brain metastasis status. Gefitinib was associated with more grade 3/4 liver dysfunction, but tended to cause lower rates of dose reduction, treatment discontinuation, total grade 3/4 adverse events (RR, 0.78; 95% CI 0.65 to 0.94), and a number of specific adverse events such as rash and diarrhea. No solid evidence was found that afatinib had greater efficacy than gefitinib or erlotinib in first-line treatment of EGFR-mutant NSCLC. However, afatinib was more effective than erlotinib as second-line treatment of patients with advanced squamous cell carcinoma. The grade 3/4 adverse events rate of afatinib was comparable to that of erlotinib but higher than that of gefitinib.

show abstract

Section: Resultsmentioning

confidence: 99%

Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: A meta‐analysis

Yang

Hackshaw

Feng

et al. 2017

Intl Journal of Cancer

184

121

View full text Add to dashboard Cite

show abstract

“…Literature Involved in the Study. Totally, 522 references were initially obtained, 116 duplicates were eliminated, and 14 RCTs were eventually involved in the study after further screening by reading the title, the abstract, and the whole text [14][15][16][17][18][19][20][21][22][23][24][25][26][27]. The screening procedure is shown in Figure 1.…”

Section: Literature Screening and Basic Characteristics Of Thementioning

confidence: 99%

Efficacy and Safety of Pemetrexed and Gefitinib in the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis

Zhang¹,

Wang²,

Xiao³

et al. 2021

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Object. This study is aimed at evaluating the efficacy and safety of pemetrexed and gefitinib in the treatment of non-small-cell lung cancer (NSCLC). Methods. Databases, including PubMed, the Cochrane Library, Embase, CNKI, and Web of Science, were applied to search for randomized controlled trials (RCTs) about the use of pemetrexed and gefitinib in the second-line treatment of locally advanced and metastatic NSCLC from database foundation to April 2020. Meta-analysis was conducted using the RevMan 5.3 software. Primary outcomes included progression-free survival (PFS) and overall survival (OS), and secondary outcomes included objective response rate (ORR), disease control rate (DCR), and all grades of drug-related adverse events (AEs). Results. Totally, 14 RCTs and 1,334 patients were involved in the study. The results of meta-analysis showed that compared with pemetrexed, gefitinib was not superior in improving ORR ( P = 0.21 ), DCR ( P = 0.52 ), PFS ( P = 0.41 ), and OS ( P = 0.79 ). Subgroup analysis showed that in patients with mutant EGFR ( P = 0.08 ) and wild-type EGFR ( P = 0.80 ), both pemetrexed and gefitinib produced a similar effect on PFS. In terms of safety, the incidence of rash ( P < 0.00001 ) and diarrhea ( P = 0.0005 ) in the gefitinib group was significantly higher than those in the pemetrexed group, while the occurrence of neutropenia ( P = 0.01 ) and fatigue ( P = 0.02 ) was significantly lower. Conclusion. Gefitinib and pemetrexed showed similar efficacy and safety, regardless of the type of EGFR. Both gefitinib and pemetrexed can be used as conventional drugs for the second-line treatment of locally advanced and metastatic NSCLC.

show abstract

The current situation of Sunitinib in treating non-small cell lung cancer

Yang

Sun

Guo

2012

Chin. -Ger. J. Clin. Oncol.

View full text Add to dashboard Cite

Sunitinib malate is one of the multitargeted tyrosine kinase inhibitor, which are being used in clinic. It can inhibit more than 80 kinds of receptor`s tyrosine kinase, including epidermal growth factor receptor (EGFR), platelet-derived growth factor receptors, vascular endothelial growth factor receptors (VEGFR), etc. And tyrosine kinase inhibitor is involved in connection with the generation and progression of many kinds of cancer including lung cancer. Several studies have evaluated the effect of Sunitinib on non-small cell lung cancer (NSCLC), by single agent, continuous daily dosing or in combination with chemotherapeutics (with docetaxel or gemcitabine plus cisplatin), which all showed certain effect. The test of Sunitinib in combination with gemcitabine plus cisplatin for advanced NSCLC shown that at the maximum tolerated dose: oral Sunitinib 37.5 mg/day intermittently (Schedule 2/1: 2 weeks on treatment, 1 week off treatment) schedule with intravenous infusions of gemcitabine (1000 mg/m 2 days 1, 8) and cisplatin (80 mg/m 2 day 1), administered in 3-week cycles, 66.7% patients achieved partial responses. And adverse effects were mild to moderate in severity (grades 1 to 2). Therapy was generally well tolerated. In summary, all the evidence above suggests that Sunitinib may play an important role in the treating of NSCLC.

show abstract

Clinical observation of pemetrexed on advanced non-small-cell lung cancer

Cited by 4 publications

References 14 publications

Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: A meta‐analysis

Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: A meta‐analysis

Efficacy and Safety of Pemetrexed and Gefitinib in the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis

The current situation of Sunitinib in treating non-small cell lung cancer

Contact Info

Product

Resources

About